Web Results


Pfizer, Inc., 562 F.3d 163. (2d Cir. 2009). In Sosa v. Alvarez-Machain,1 the Supreme ... Al- though the plaintiffs also initially alleged that the Nigerian govern- .


Aug 3, 2018 ... Al Haj et al v. Pfizer Inc, No. 1:2017cv06730 - Document 83 (N.D. Ill. 2018) case opinion from the Northern District of Illinois US Federal District ...


Jan 19, 2018 ... In Wyeth v. Levine, the Supreme Court held that claims against a manufacturer of a brand-name prescription drug for failure to warn adequately ...


Jun 1, 2018 ... 2018 UnitedHealthcare Services, Inc. 1. UnitedHealthcare .... Pfizer Inc. New York, NY. December ... Bril V, England J, Franklin GM, et al. ... Stubblefield, MD, Burstein, HJ, Burton, AW NCCN Task Force Report: Management of.


Corp. v. Cosprophar, Inc., 32 F.3d 690, 692 (2d Cir. 1994);. Upjohn Co. v. MacMurdo ..... 9 I. Scott Bass et al., Off-Label Promotion: Is FDA's Final Guidance on ..... class action by medical insurers against Pfizer and Warner- ...... Stubblefield, 319.


Jan 15, 2016 ... Gianatassio et al. have now devised a general use for these and related molecular curiosities. .... With a reliable route to stock solutions of propellane A ( after codistillation with Et2O ... Indeed, this chemistry has already been field- tested at Pfizer (for ..... H. Prokopcová,; S. D. Bergman,; K. Aelvoet,; V. Smout, ...


Mar 4, 2016 ... The 9 N370S homozygotes had a mean AAO of GD of 37.4 years vs 18.6 .... from BioMarin, Genzyme (Sanofi), Pfizer, and Shire and has served on the editorial boards of Orphanet and JIMD. ... of its scientific advisory board, and has stock options with the company; ... Tayebi N, Walker J, Stubblefield B, et al.


Mar 12, 2018 ... This includes employment, consultancies, honoraria, stock .... Sidransky E, Tsuji S, Stubblefield BK, et al. ..... Cullen V, Sardi SP, Ng J, et al.


1997;145:335-8. 10 Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, etal. ... et al. Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal ..... grants from pharmaceutical companies (Merck, Pfizer, Johnson and. Johnson .... interval cancers (42 v 49 per 100 000 person years).